Pipelines

© GettyImages/Design Cells

4D Pharma expanding clinical data in multiple indications

By Jane Byrne

Live biotherapeutic product (LBP) developer, 4D Pharma, says it is building a ‘strong body of evidence’ for its portfolio of bacterial strains in relation to cancer, asthma, and neurodegenerative diseases, while the company also calls its recent dual...

© GettyImages/Urupong

Dispatches from Bio Digital 2021

Pfizer CEO: ‘There is renewed hope and trust in science’

By Jane Byrne

A lesson learnt from the COVID-19 pandemic was that human ingenuity prevailed and resolved an issue that challenged the world; the crisis also reinforced faith in the power of science, said Dr Albert Bourla, CEO of Pfizer, in a keynote interview during...

© GettyImages/Fokusiert

Moderna starts process to obtain BLA for Covid-19 shot

By Jane Byrne

Moderna has initiated the rolling submission process with the US Food and Drug Administration (FDA) for a Biologics License Application (BLA) to distribute and market its mRNA COVID-19 vaccine in the US for use in individuals aged 18 and older.

Chicago emerging as life science and biopharma hub

Chicago emerging as a life science and biopharma hub

By Jane Byrne

Many turn to Boston and North Carolina’s Research Triangle to set up life science companies, but Chicago is now also fast becoming a draw in this respect. The city is emerging as a life science and biopharma hub and seems poised for even further growth,...

© GettyImages/Dilok Klaisataporn

PPD adds cell and gene therapy testing capabilities to Irish site

By Jane Byrne

US contract research organization, PPD Inc, is expanding its Athlone, Ireland, GMP laboratory, significantly increasing the size of its current facility and adding cell and gene therapy (CGT) testing to the operation’s portfolio of services.

© GettyImages/Lars Neumann

KIYATEC flags checkpoint inhibitor response prediction milestone

By Jane Byrne

US company, KIYATEC, says a new study has shown that its immune-modified ex vivo platform can measure treatment response through direct interaction between a patient's cancer and infiltrating immune cells, and immuno-oncology agents.